[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-338380-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-338380-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","more-t-cell-receptors-to-the-rascue-in-cancer-tcr-t-and-kras-g12v","More T cell receptors to the RAScue in cancer - TCR-T and KRAS G12V","","Genetically engineered T cell receptor therapies (TCR-T) are highlighted as a promising cancer immunotherapy, with key challenges including selecting optimal TCRs and tumor antigens while matching the correct HLA restriction. The commentary summarizes work using in vitro assays to characterize multiple HLA-A*03:01- or HLA-A*11:01-restricted TCRs targeting the KRAS G12V mutation. It contrasts TCR-T with TIL therapy, discusses antigen requirements, and considers strategies to expand eligibility via broader off-the-shelf TCR libraries.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/more-t-cell-receptors-to-the-rascue-in-cancer-tcr-t-and-kras-g12v/338380/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/more-t-cell-receptors-to-the-rascue-in-cancer-tcr-t-and-kras-g12v/338380.png","ImageObject",300,407,{"name":42,"@type":43},"Skyler","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What makes TCR-T a promising approach for cancer treatment?","Question",{"text":63,"@type":64},"TCR-T uses genetically engineered T cells expressing tumor-reactive TCRs, enabling the targeting of cancer cells. Success depends on identifying suitable TCRs and tumor antigens and ensuring correct HLA restriction matching.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How do Bear and colleagues characterize the KRAS G12V–targeting TCRs?",{"text":68,"@type":64},"They report using in vitro assays to characterize four HLA-A*03:01– or HLA-A*11:01–restricted TCRs that target the KRAS G12V mutation, using TCRs derived from healthy donors or patients after mutant KRAS vaccination.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is eligibility for TCR-T limited, and how can it be expanded?",{"text":72,"@type":64},"Eligibility is constrained because each TCR can treat only patients who both express the targeted tumor antigen and have the matching HLA restriction element. A proposed strategy is to identify additional TCRs restricted by different HLA alleles to build a larger off-the-shelf TCR library.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},338380,1790187423,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":30,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":30,"preview_urls":145},2336464648746,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","The Journal of Clinical Investigation COMMENTARY  \nMore T cell receptors to the RAScue in cancer?  \nEric Tran  \nEarle A. Chiles Research Institute, a division of Providence Cancer Institute, Portland, Oregon, USA.  \nTreatment with T cells genetically engineered to express tumor-reactive T cell receptors (TCRs), known as TCR-gene therapy (TCR-T), is a promising immunotherapeutic approach for patients with cancer. The identification of optimal TCRsto use and tumor antigens to target are key considerations for TCR-T. In this issue of the JCI, Bear and colleagues report on their use of in vitro assays to characterize four HLA-A*03:01– or HLA-A*11:01–restricted TCRs targeting the oncogenic KRAS G12V mutation. TheTCRs were derived from healthy donors or patients with pancreatic cancer who had received a vaccine against mutant KRAS. The most promising TCRs warrant testing inpatients with KRAS G12V–positive cancers.  \nT cell receptor–based cell therapies against solid cancers The administration of in vitro–expanded tumor-infiltrating lymphocytes (TILs) was the first T cell receptor–based (TCRbased) cellular therapy to target solid cancers. This approach was pioneered by Rosenberg and colleagues at the National Cancer Institute (NCI) (1) and entails obtaining tumor material from a patient, followed by large-scale in vitro expansion of T cells within the TIL and infusion of these cells into the patient followed by interleukin-2 (2) . Notably, this therapy can mediate durable clinical responses in some patients with metastatic melanoma (3–5), which led to its approval by the FDA for this indication in February 2024. TIL therapy also has mediated clinical responses in epithelialderived cancers, and like in melanoma, responses largely were driven by T cells harboring TCRs that target tumor antigens, such as neoantigens derived from cancer mutations (6) .  \nThe ability to isolate tumor-reactive TCR sequences and advances in T cell engineering permitted the development of TCR-gene therapy (TCR-T), a strategy that involves the in vitro genetic insertion of a tumor antigen–reactive TCR into the peripheral blood T cells of a patient, followed by expansion and infusion of the gene-modified T cells back into the patient (2). This process can generate a large number of tumor-antigen–reactive T cells. Unlike TIL therapy, which can only be used to treat the autologous patient, TCR-T allows for an “off-the-shelf” TCR that can be used to treat any patient whose tumors express the targeted antigen and matching HLA-restriction element ofthe TCR.  \nThe targeted antigen is a key consideration forTCR-T; optimal tumor antigens are tumor specific, to avoid toxicity in healthy tissue, and essential for maintenance of the malignant phenotype. Oncogenic viruses and driver mutations fulfill these criteria.  \nIndeed, regression of metastatic epithelial-derived cancer has been observed in  \nRelated Article: [https://doi.org/10.1172/JCI175790](https://doi.org/10.1172/JCI175790)  \nConflict of interest: ET is a member of the scientific advisory board of Turnstone Biologics and a consultant for AstraZeneca and Pathfinder Oncology. ET received research funding from the Kuni Foundation. ET also is an inventor on patents “Anti-KRAS-G12D T cell receptors”(US 11,208,456); “Anti-KRAS-G12D T cell receptors”(US 11,897,933);“Anti-KRAS-G12D T cell receptors”(US 11,840,561); and pending patent “Anti-KRAS-G12D T cell receptors”  \n(US20240209059) .  \nCopyright: © 2024, Tran et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.  \nReference information: J Clin Invest. 2024;134(21):e184782 . [https://doi.org/10.1172/JCI184782](https://doi.org/10.1172/JCI184782) .  \npatients receiving TCR-T targeting oncogenic HPV16-E6 or E7 (7, 8) or the hotspot mutations KRAS G12D (9) or TP53 R175H (10). A major limitation of TCR-T, however, is that a given TCR only can treat an often-small subset of patients due to the dual re","cbCaiiLZ0tpOAQ8Y","https://ap.wps.com/l/cbCaiiLZ0tpOAQ8Y","pdf",116713,"English","# TCR-gene therapy (TCR-T) in cancer\n## Using in vitro assays to characterize KRAS G12V–reactive TCRs\n## TCR-T versus TIL therapy and the need for HLA/antigen matching\n## Extending eligibility through broader off-the-shelf TCR libraries","[{\"question\":\"What makes TCR-T a promising approach for cancer treatment?\",\"answer\":\"TCR-T uses genetically engineered T cells expressing tumor-reactive TCRs, enabling the targeting of cancer cells. Success depends on identifying suitable TCRs and tumor antigens and ensuring correct HLA restriction matching.\"},{\"question\":\"How do Bear and colleagues characterize the KRAS G12V–targeting TCRs?\",\"answer\":\"They report using in vitro assays to characterize four HLA-A*03:01– or HLA-A*11:01–restricted TCRs that target the KRAS G12V mutation, using TCRs derived from healthy donors or patients after mutant KRAS vaccination.\"},{\"question\":\"Why is eligibility for TCR-T limited, and how can it be expanded?\",\"answer\":\"Eligibility is constrained because each TCR can treat only patients who both express the targeted tumor antigen and have the matching HLA restriction element. A proposed strategy is to identify additional TCRs restricted by different HLA alleles to build a larger off-the-shelf TCR library.\"}]","More T cell receptors to the RAScue in cancer - TCR-T and KRAS G12V | PDF",1790023358,[146,150,154],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/35fdbbab74428cf7d8b0703f1a23988f.webp",983,1315,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/205eeed7458bef4ef49a8d723860471a.webp",982,1314,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ef720a9aba646a52bdb4238890dc0eb6.webp",981,1312]